Physiopathology of the dyskinesias induced by L-dopa
Grandas, F.; López-Ariztegui, N.
Revista de Neurologia 25(Suppl 2): S151-S156
1997
ISSN/ISBN: 0210-0010 PMID: 9280682 Document Number: 476899
Dyskinesias are one of most frequent motor complications of parkinsonian patients on chronic levodopa treatment. This article reviews their clinical characteristics, risk factors, pathophysiology and possible therapeutical approaches.
Document emailed within 1 workday
Related Documents
Maurel, F.; Lilliu, H.; Le-Pen, C. 2001: Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease Revue Neurologique (Paris) 157(5): 507-514Mazars, G.; Merienne, L.; Gotusso, C.; Soussaline, M. 1970: Dyskinesias of the upper limb associated with dyskinesias of cephalic orientation. Study of 45 cases and presentation of a film Revue Neurologique (Paris) 122(4): 275-277
Jankovic, J.; Lai, E.C.; Krauss, J.; Grossman, R. 1999: Surgical treatment of levodopa-induced dyskinesias Advances in Neurology 80: 603-609
Rascol, O. 2000: Medical treatment of levodopa-induced dyskinesias Annals of Neurology 47(4 Suppl 1): S179-S188
Obeso, J.A.; Rodriguez-Oroz, M.C.; Rodriguez, M.; DeLong, M.R.; Olanow, C.W. 2000: Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model Annals of Neurology 47(4 Suppl 1): S22
Demaret, A. 1970: Comparison between the paroxysmal dyskinesias (neurodyslepsy) induced by neuroleptics in humans and early behavior patterns in newborns Acta Psychiatrica Belgica 70(4): 552-561
Van den Driessche, J.; Eben-Moussi, E. 1971: Attempted prevention of vomiting induced by L-dopa in the dog Pathologie-Biologie 19(15): 797-800
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Hansson, C.; Rorsman, H.; Rosengren, E. 1981: Pronounced formation of 5-OH-dopa at enzymatic oxidation of DOPA in the presence of ascorbic acid Acta Dermato-Venereologica 61(2): 147-148
Bizzarri, B.Mattia.; Tortolini, S.; Rotelli, L.; Botta, G.; Saladino, R. 2015: Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity Current Medicinal Chemistry 22(36): 4138-4165
Riley, P.A. 1999: The great DOPA mystery: the source and significance of DOPA in phase i melanogenesis Cellular and Molecular Biology 45(7): 951-960
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Blair, M.L.; Reid, I.A.; Ganong, W.F. 1977: Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs Journal of Pharmacology and Experimental Therapeutics 202(1): 209-215
Zabel, M. 1979: Ultrastructure of thyroid C cells following long-term administration of 1-DOPA or alpha-methyl-DOPA Acta Medica Polona 20(1): 53-54
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Vasil'ev, V.N. 1980: Effect of a test with 0.1 g of L-DOPA on the dynamics of urinary excretion of catecholamines and DOPA in schizophrenic patients Voprosy Meditsinskoi Khimii 26(6): 782-786
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Pontiroli, A.E.; Castegnaro, E.; Vettaro, M.P.; Viberti, G.C.; Pozza, G. 1977: Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine Acta Endocrinologica 84(1): 36-44
Bryson, G.; Bischoff, F. 1971: A scatter-jump syndrome with gnawing and fighting induced by L-dopa in mice Research Communications in Chemical Pathology and Pharmacology 2(4): 469-476